RVSV-ZEBOV vaccine

RVSV-ZEBOV vaccine is a vaccine used to protect against Ebola virus disease. It was developed by the Public Health Agency of Canada and is now licensed to Merck & Co. The vaccine is a recombinant, replication-competent vesicular stomatitis virus-based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus.

Development

The development of the RVSV-ZEBOV vaccine began in the early 2000s at the National Microbiology Laboratory of the Public Health Agency of Canada. The vaccine was then licensed to NewLink Genetics, which was subsequently acquired by Merck & Co.

Efficacy

The RVSV-ZEBOV vaccine has been shown to be effective in preventing Ebola virus disease in clinical trials. A trial conducted in Guinea during the 2014-2016 Ebola outbreak showed that the vaccine was highly effective.

Usage

The RVSV-ZEBOV vaccine is used in a "ring vaccination" approach, where all people who have come into contact with an Ebola patient are vaccinated to prevent the spread of the disease. It is also used to vaccinate healthcare workers who are at high risk of infection.

Side Effects

Common side effects of the RVSV-ZEBOV vaccine include headache, fatigue, muscle pain, and fever. Serious side effects are rare but can include allergic reactions.

See Also

• Ebola virus disease
• Vaccine
• Public Health Agency of Canada
• Merck & Co
• Vesicular stomatitis virus
• Zaire Ebolavirus
• National Microbiology Laboratory
• NewLink Genetics
• Guinea
• Ebola outbreak

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia